Phase 3 trial in 1054 adults aged 18-55 previously given three BNT162b2 doses: a fourth dose of bivalent BA.1-adapted vaccine (30 or 60 μg) or monovalent BA.1 (60 μg) was well tolerated; reactions and AEs were slightly more frequent with 60 μg monovalent.
RCTn = 1,054
Winokur et al. Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old